Baishan Jiang
Impact in
- Oncology top 5%
- Peptidase Inhibition and Analysis
- Cancer-related Molecular Pathways
- CAR-T cell therapy research
- Hematology top 5%
- Multiple Myeloma Research and Treatments
Papers in
- Oncology 14
- Cancer-related Molecular Pathways 5
- Peptidase Inhibition and Analysis 4
-
- Protein Degradation and Inhibitors 12
- Ubiquitin and proteasome pathways 10
- RNA modifications and cancer 3
- CRISPR and Genetic Engineering 3
- Co-authors
- Nathanael S. Gray (13 shared papers)Tinghu Zhang (10 shared papers)Eric S. Fischer (7 shared papers)Yanke Liang (4 shared papers)Nicholas P. Kwiatkowski (7 shared papers)Katherine A. Donovan (5 shared papers)Georg E. Winter (4 shared papers)Eric S. Wang (2 shared papers)
- Journals
- Cell chemical biology (4 papers)Nature Chemical Biology (3 papers)Nature Cancer (2 papers)Science Advances (2 papers)Advanced Science (2 papers)
- Partner nations
- United StatesChinaGermany
In The Last Decade
Baishan Jiang
36 papers receiving 2.3k citations
Baishan Jiang's Hit Papers
Peers
Comparison fields: 5 of 91
- Oncology 841
- Hematology 286
- Molecular Biology 1.7k
- Pulmonary and Respiratory Medicine 324
- Genetics 101
Countries citing papers authored by Baishan Jiang
This map shows the geographic impact of Baishan Jiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Baishan Jiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Baishan Jiang more than expected).
Fields of papers citing papers by Baishan Jiang
This network shows the impact of papers produced by Baishan Jiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Baishan Jiang. The network helps show where Baishan Jiang may publish in the future.
Co-authors
The 25 scholars most cited alongside Baishan Jiang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 39 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation Hit paper breakdown → | 2017 | 445 |
| 2 | 2020 | 276 | |
| 3 | 2019 | 241 | |
| 4 | 2018 | 222 | |
| 5 | 2017 | 148 | |
| 6 | 2021 | 123 | |
| 7 | 2021 | 112 | |
| 8 | 2022 | 111 | |
| 9 | 2021 | 108 | |
| 10 | 2018 | 70 | |
| 11 | 2018 | 68 | |
| 12 | 2020 | 60 | |
| 13 | 2017 | 50 | |
| 14 | 2021 | 46 | |
| 15 | 2020 | 44 | |
| 16 | 2021 | 38 | |
| 17 | 2023 | 35 | |
| 18 | 2013 | 25 | |
| 19 | 2010 | 19 | |
| 20 | 2014 | 19 |
About Baishan Jiang
Baishan Jiang is a scholar working on Oncology, Molecular Biology, Hematology, Immunology and Organic Chemistry, having authored 39 papers that have together received 2.4k indexed citations. Recurring topics across this work include Protein Degradation and Inhibitors (12 papers), Ubiquitin and proteasome pathways (10 papers), Cancer-related Molecular Pathways (5 papers), Peptidase Inhibition and Analysis (4 papers), Autophagy in Disease and Therapy (3 papers), RNA modifications and cancer (3 papers), Advanced Breast Cancer Therapies (3 papers) and CRISPR and Genetic Engineering (3 papers). The work is most often cited by research in Oncology (841 citations), Hematology (286 citations), Molecular Biology (1.7k citations), Pulmonary and Respiratory Medicine (324 citations) and Genetics (101 citations). Baishan Jiang has collaborated with scholars based in United States, China and Germany. Frequent co-authors include Nathanael S. Gray, Tinghu Zhang, Eric S. Fischer, Yanke Liang, Nicholas P. Kwiatkowski, Katherine A. Donovan, Georg E. Winter, Eric S. Wang, James E. Bradner and Zainab M. Doctor. Their work appears in journals such as Cell chemical biology, Nature Chemical Biology, Nature Cancer, Science Advances and Advanced Science.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.